StatLab Medical Products Expands Global Horizons
StatLab Medical Products, a distinguished developer and manufacturer of medical diagnostic supplies, is embarking on an exciting new chapter through its recent acquisition of Myr, a prominent Spanish histology equipment manufacturer. This strategic move positions StatLab to significantly broaden its product portfolio and enhance its international presence.
About the Acquisition
The acquisition of Especialidades Médicas Myr, S.L. marks a pivotal moment for StatLab, allowing the company to integrate Myr's extensive product offerings and manufacturing capabilities. With Myr having established a reliable distributor network worldwide, this partnership unlocks new opportunities for StatLab in emerging markets. The synergy between the two companies will undoubtedly boost growth and enhance service capabilities in various regions.
Adding Value to StatLab
Founded over 30 years ago and headquartered near Tarragona, Spain, Myr has built a reputation for quality in histology equipment, including essential tools for tissue processing, embedding, sectioning, and staining. StatLab will benefit not only from Myr's impressive manufacturing facilities but also from its skilled team dedicated to producing high-quality histology solutions.
Insights from Company Leaders
This acquisition was celebrated by StatLab's CEO, Sung-Dae Hong, who emphasized the importance of Myr's complementary product lineup. "The addition of Myr’s equipment diversifies our offerings and strengthens our strategic footprint in key European markets alongside our Diapath and CellPath brands," he remarked. This partnership sets the foundation for expanding into new markets and maximizing the capabilities of both organizations.
Commitment to Customer Needs
Paco Ruiz, the CEO and Founder of Myr, shared his enthusiasm about joining forces with StatLab: "Our decision to partner with StatLab stems from a mutual dedication to fulfilling customer demands. This collaboration presents a remarkable opportunity to grow the Myr brand while enhancing our product offerings. I am enthusiastic about the potential for collaboration and the shared vision of delivering outstanding solutions to our customers."
About StatLab Medical Products
Since 1976, StatLab Medical Products has been devoted to supporting anatomic pathology laboratories in delivering optimal patient care. The company boasts an extensive portfolio of self-manufactured consumables and labeling equipment, produced across nine manufacturing sites in the United States, United Kingdom, and Europe. With over 750 employees committed to a mission-driven approach, StatLab ensures a dependable supply chain of high-quality products while continuously focusing on innovation and reliability in customer service.
About Myr Histology Equipment
Myr's dedication to producing advanced histology instruments has positioned it as a key player in the industry. With their unwavering commitment to quality and customer satisfaction, Myr has consistently delivered products that meet the demands of laboratory settings worldwide. This merger with StatLab stands to amplify their impact in the histology market.
Frequently Asked Questions
What is the significance of StatLab’s acquisition of Myr?
This acquisition significantly enhances StatLab's product offerings and expands its global reach, particularly in the histology equipment market.
How long has Myr been in operation?
Myr has been operating for over 30 years, becoming a trusted name in histology equipment manufacturing.
What benefits does the partnership bring?
The partnership allows both companies to leverage each other's strengths, diversify product offerings, and tap into new emerging markets.
Who leads StatLab Medical Products?
Sung-Dae Hong serves as the CEO of StatLab Medical Products, guiding the company's strategic direction and growth initiatives.
What is the focus of both companies following this acquisition?
Both companies are committed to enhancing customer service, expanding product lines, and ensuring high-quality standards throughout their operations.
